Profund Advisors LLC Increases Holdings in Halozyme Therapeutics, Inc. $HALO

Profund Advisors LLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 46.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,100 shares of the biopharmaceutical company’s stock after acquiring an additional 11,469 shares during the period. Profund Advisors LLC’s holdings in Halozyme Therapeutics were worth $2,430,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in HALO. Empowered Funds LLC purchased a new position in shares of Halozyme Therapeutics in the first quarter valued at about $755,000. Acadian Asset Management LLC purchased a new position in shares of Halozyme Therapeutics in the first quarter valued at about $195,000. Hsbc Holdings PLC increased its holdings in shares of Halozyme Therapeutics by 117.1% in the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 174 shares during the last quarter. Finally, Baird Financial Group Inc. increased its holdings in shares of Halozyme Therapeutics by 6.2% in the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $577,000 after purchasing an additional 650 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Trading Up 1.9%

Shares of NASDAQ HALO opened at $68.73 on Wednesday. The business’s 50 day moving average is $65.67 and its two-hundred day moving average is $68.70. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. Halozyme Therapeutics, Inc. has a 1-year low of $51.06 and a 1-year high of $82.22. The stock has a market capitalization of $8.15 billion, a P/E ratio of 24.72, a PEG ratio of 0.28 and a beta of 0.89.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. During the same period in the previous year, the firm posted $1.11 earnings per share. The firm’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 7.66 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on HALO shares. Morgan Stanley reduced their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Wells Fargo & Company lifted their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. Benchmark lifted their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Finally, HC Wainwright lifted their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $80.67.

Insider Activity

In other news, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $63.48, for a total transaction of $103,155.00. Following the transaction, the director owned 38,498 shares of the company’s stock, valued at approximately $2,443,853.04. This represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $64.24, for a total value of $1,284,800.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $49,322,187.20. This represents a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 120,482 shares of company stock valued at $8,200,842. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.